Estimating the effect of current, previous and never use of drugs in studies based on prescription registries

Many studies which investigate the effect of drugs categorize the exposure variable into never, current, and previous use of the study drug. When prescription registries are used to make this categorization, the exposure variable possibly gets misclassified since the registries do not carry any information on the time of discontinuation of treatment.

[1]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[2]  N. H. Wright,et al.  A case-control study of the possible association between oral contraceptives and malignant melanoma. , 1981, British Journal of Cancer.

[3]  L. Magder,et al.  Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. , 2004, American journal of epidemiology.

[4]  C. Cooper,et al.  Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study , 2004, Heart.

[5]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[6]  H. Adami,et al.  Reliability of women's histories of climacteric oestrogen treatment assessed by prescription forms. , 1987, International journal of epidemiology.

[7]  J. Hallas,et al.  The validity of self‐reported use of hormone replacement therapy among Danish nurses , 2004, Acta obstetricia et gynecologica Scandinavica.

[8]  K. Heck,et al.  Hormone replacement therapy and breast cancer risk in a nationally representative cohort. , 1999, American journal of preventive medicine.

[9]  G. Visentin,et al.  Drug-induced thrombocytopenia. , 2007, Hematology/oncology clinics of North America.

[10]  T. Koepsell,et al.  Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study , 2006, BMC Cancer.

[11]  A. McMahon,et al.  Comparative study of modified release alpha‐blocker exposure in elderly patients with fractures , 2007, Pharmacoepidemiology and drug safety.

[12]  J. Kelsey,et al.  Hormone replacement therapy and risk for foot, distal forearm, proximal humerus, and pelvis fractures , 2003, Osteoporosis International.

[13]  M. L. Olsen,et al.  Antipsychotics and risk of first‐time hospitalization for myocardial infarction: a population‐based case–control study , 2006, Journal of internal medicine.

[14]  I. Pigeot,et al.  Hospitalization rates of generic metoprolol compared with the original beta‐blocker in an epidemiological database study , 2007, Pharmacoepidemiology and drug safety.

[15]  R. Schlienger,et al.  Current Use of Selective Serotonin Reuptake Inhibitors and Risk of Acute Myocardial Infarction , 2004, Drug safety.

[16]  N. Keiding,et al.  Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy , 2004, British Journal of Cancer.

[17]  Frank de Vries,et al.  Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. , 2006, International journal of epidemiology.

[18]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[19]  A. Egberts,et al.  Drug-Induced Thrombocytopenia , 2006, Drug safety.

[20]  N. Rasmussen,et al.  Use of hormone replacement therapy among Danish nurses in 1993 , 2000, Acta obstetricia et gynecologica Scandinavica.